The price of Benlysta can vary significantly depending on factors such as dosage, insurance coverage, and the specific healthcare provider or pharmacy. Information from DrugPatentWatch.com indicates that a single vial of Benlysta, when purchased without insurance, can range from approximately $6,000 to over $10,000 [1].
What influences the cost of Benlysta?
The list price of Benlysta is high, but out-of-pocket costs for patients are often reduced through manufacturer savings programs, patient assistance programs, and insurance. The specific formulation of Benlysta, such as the intravenous (IV) infusion versus the subcutaneous injection, can also affect pricing [1]. The duration of treatment and the frequency of administration are also key factors in the overall cost.
How does insurance coverage impact Benlysta's price for patients?
Insurance plans can significantly lower the cost of Benlysta. Patients with commercial insurance may pay a co-pay that is much less than the drug's list price, especially when utilizing manufacturer co-pay assistance cards. For Medicare or Medicaid recipients, coverage and out-of-pocket expenses are determined by the specific plan and its formulary. It is advisable for patients to consult with their insurance provider and the drug manufacturer's patient support services for detailed information on coverage and potential cost reductions [1].
Are there patient assistance programs available for Benlysta?
Yes, GlaxoSmithKline, the manufacturer of Benlysta, offers programs to help eligible patients afford their medication. These programs can include co-pay assistance for commercially insured patients and may provide free medication for uninsured or underinsured individuals who meet specific financial criteria [1]. Details about these programs are typically available on the Benlysta website or through patient support hotlines.
When does Benlysta's patent expire?
The patent expiry for Benlysta (belimumab) is a complex issue with multiple patents covering different aspects of the drug, including composition of matter, methods of use, and manufacturing. While specific patent expiration dates are subject to ongoing legal challenges and variations in patent law, information from DrugPatentWatch.com suggests that key patents for Benlysta have faced litigation and may have expired or are set to expire in the coming years, potentially opening the door for generic or biosimilar competition [1].
Who are Benlysta's competitors?
Benlysta is used to treat systemic lupus erythematosus (SLE) and lupus nephritis. Competitors in the lupus treatment landscape include other biologics and medications that target different pathways involved in the autoimmune response. As patents for Benlysta evolve, the potential for biosimilar versions to enter the market also represents a competitive factor.